All Pharma News
The unraveling of EQRx’s low-cost drug dream

The unraveling of EQRx’s low-cost drug dream
Annalee Armstrong FIERCE BIOTECH
05 Oct 2023
Share Share
EQRx had limited buyer interest, tried acquiring other companies

EQRx had limited buyer interest, tried acquiring other companies
Kyle LaHucik ENDPTS
04 Oct 2023
Share Share
Lynk’s JAK1 inhibitor improves severity, itching in eczema study

Lynk’s JAK1 inhibitor improves severity, itching in eczema study
Gabrielle Masson FIERCE BIOTECH
09 Aug 2023
Share Share
Revolution Medicines, Inc. to Acquire EQRx, Inc.

Revolution Medicines, Inc. to Acquire EQRx, Inc.
GLOBENEWSWIRE
01 Aug 2023
Share Share
EQRx sells itself to another Revolution Medicines, in all-stock deal

EQRx sells itself to another Revolution Medicines, in all-stock deal
Max Gelman ENDPTS
01 Aug 2023
Share Share
EQRx`s low cost drug dream ends in Revolution

EQRx`s low cost drug dream ends in Revolution
James Waldron FIERCE BIOTECH
01 Aug 2023
Share Share
EQRx abandons low cost drug plan, cuts programs and staff

EQRx abandons low cost drug plan, cuts programs and staff
Gabrielle Masson FIERCE BIOTECH
09 May 2023
Share Share
EQRx to trim more than 40 staffers in restructuring maneuver

EQRx to trim more than 40 staffers in restructuring maneuver
Paul Schloesser ENDPTS
23 Feb 2023
Share Share
Impel, Cybin, EQRx trim head counts to prioritize easy wins

Impel, Cybin, EQRx trim head counts to prioritize easy wins
James Waldron FIERCE BIOTECH
23 Feb 2023
Share Share
Nearly a year after his SPAC combines with EQRx, Eli Casdin resigns from board

Nearly a year after his SPAC combines with EQRx, Eli Casdin resigns from board
ENDPTS
28 Nov 2022
Share Share